miR-762 activation confers acquired resistance to gefitinib in non-small cell lung cancer

BACKGROUND: Epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors (TKIs) (e.g. gefitinib) currently remain the first-line treatment for patients with advanced non-small-cell lung cancer (NSCLC) with activating EGFR mutation. However, acquired resistance to gefitinib, which occurs freque...

Descripción completa

Detalles Bibliográficos
Autores principales: Ge, Peng, Cao, Lei, Chen, Xin, Jing, Ruijun, Yue, Wanxia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6905032/
https://www.ncbi.nlm.nih.gov/pubmed/31823748
http://dx.doi.org/10.1186/s12885-019-6416-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6905032/
https://www.ncbi.nlm.nih.gov/pubmed/31823748
http://dx.doi.org/10.1186/s12885-019-6416-4

Ejemplares similares